Publication Name	World Journal of Clinical Cases
Manuscript ID	56432
Country	United States

Received	2020-05-23 02:47
Peer-Review Started	2020-05-20 01:14
To Make the First Decision
Return for Revision	2020-06-19 23:48
Revised	2020-06-30 13:01
Second Decision	2020-08-21 12:03
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2020-08-21 21:06
Articles in Press	2020-08-21 21:06
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2020-09-14 06:25
Publish the Manuscript Online	2020-09-22 03:17

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Harry Dang, Jiyuan Sun, Guoliang Wang, Gregory Renner, Lester Layfield and Jaffar Hilli
ORCID	Author(s) ORCID Number Harry Dang http://orcid.org/0000-0001-9131-7406 Jiyuan Sun http://orcid.org/0000-0003-3912-1400 Guoliang Wang http://orcid.org/0000-0003-3314-4206 Gregory Renner http://orcid.org/0000-0001-9760-0528 Lester Layfield http://orcid.org/0000-0003-1344-6506 Jaffar Hilli http://orcid.org/0000-0002-5966-3728
Funding Agency and Grant Number
Corresponding Author	Jaffar Hilli, MD, Doctor, Department of Hematology-Oncology, University of Missouri, 1 Hospital Dr, Columbia, MO 65212, United States. ahmadalhillij@health.missouri.edu
Key Words	Pembrolizumab; Infliximab; Mucositis; Melanoma; Immunotherapy; Refractory
Core Tip	Grade 3-4 mucositis is a rare adverse effect of the immune checkpoint inhibitor with 2 cases reported that both responded well to steroid tapering course. We report a case of pembrolizumab-induced severe mucositis that was refractory to steroids at first but had significant improvement after administration of infliximab while continuing to be on steroid tapering course.
Publish Date	2020-09-22 03:17
Citation	Dang H, Sun J, Wang G, Renner G, Layfield L, Hilli J. Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report . World J Clin Cases 2020; 8(18): 4100-4108
URL	https://www.wjgnet.com/2307-8960/full/v8/i18/4100.htm
DOI	https://dx.doi.org/10.12998/wjcc.v8.i18.4100

Full Article (PDF)	WJCC-8-4100.pdf
Full Article (Word)	WJCC-8-4100.docx
Manuscript File	56432-Review.docx
Answering Reviewers	56432-Answering reviewers.pdf
Audio Core Tip	56432-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	56432-Conflict-of-interest statement.pdf
Copyright License Agreement	56432-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	56432-Informed consent statement.pdf
Peer-review Report	56432-Peer-review(s).pdf
Scientific Misconduct Check	56432-Scientific misconduct check.pdf
Scientific Editor Work List	56432-Scientific editor work list.pdf